These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 14964003)

  • 21. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
    Lorenz J
    Int J Clin Pract; 2003; 57(6):519-29. PubMed ID: 12918892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pooled analysis of telithromycin in the treatment of community-acquired respiratory tract infections in adults.
    Carbon C
    Infection; 2003 Oct; 31(5):308-17. PubMed ID: 14556055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The evolution of antimicrobial agents used for the management of CARTIs: a focus on a new class of antimicrobials--the ketolides.
    Sbarbaro JA
    Am J Manag Care; 2004 Oct; 10(12 Suppl):S389-99. PubMed ID: 15603248
    [No Abstract]   [Full Text] [Related]  

  • 24. [Telithromycin].
    Benes J
    Klin Mikrobiol Infekc Lek; 2004 Feb; 10(1):16-21. PubMed ID: 15100978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000).
    Kohno S; Hoban D;
    J Chemother; 2003 Aug; 15(4):335-41. PubMed ID: 12962361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections.
    Lonks JR; Goldmann DA
    Clin Infect Dis; 2005 Jun; 40(11):1657-64. PubMed ID: 15889365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Telithromycin.
    Raja A; Lebbos J; Kirkpatrick P
    Nat Rev Drug Discov; 2004 Sep; 3(9):733-4. PubMed ID: 15368658
    [No Abstract]   [Full Text] [Related]  

  • 28. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managing acute lower respiratory tract infections in an era of antibacterial resistance.
    Volturo GA; Low DE; Aghababian R
    Am J Emerg Med; 2006 May; 24(3):329-42. PubMed ID: 16635707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Telithromycin inhibits the number of viable bacteria but not lymphocyte accumulation in a murine model of chronic respiratory infection.
    Yanagihara K; Kuroki M; Higuchi N; Ohno H; Higashiyama Y; Miyazaki Y; Hirakata Y; Mukae H; Tomono K; Mizuta Y; Kadota J; Tsukamoto K; Kohno S
    Chemotherapy; 2007; 53(1):10-3. PubMed ID: 17192707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cardiovascular safety of azithromycin.
    Juurlink DN
    CMAJ; 2014 Oct; 186(15):1127-8. PubMed ID: 25096666
    [No Abstract]   [Full Text] [Related]  

  • 32. Tissue kinetics of telithromycin, the first ketolide antibacterial.
    Muller-Serieys C; Andrews J; Vacheron F; Cantalloube C
    J Antimicrob Chemother; 2004 Feb; 53(2):149-57. PubMed ID: 14729764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae.
    Okamoto H; Miyazaki S; Tateda K; Ishii Y; Yamaguchi K
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3250-2. PubMed ID: 11600393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PROTEKT US: results from the second year of this longitudinal surveillance study of antimicrobial resistance among respiratory tract pathogens isolated from paediatric and adult patients in the USA. Introduction.
    Brown SD
    J Antimicrob Chemother; 2004 Aug; 54 Suppl 1():i5. PubMed ID: 15352301
    [No Abstract]   [Full Text] [Related]  

  • 35. Long-term macrolide therapy in chronic obstructive pulmonary disease.
    Parameswaran GI; Sethi S
    CMAJ; 2014 Oct; 186(15):1148-52. PubMed ID: 25096664
    [No Abstract]   [Full Text] [Related]  

  • 36. [Resistance of infectious agents involved in low respiratory tract infections in France].
    Varon E; Houssaye S
    Med Mal Infect; 2006; 36(11-12):555-69. PubMed ID: 16962730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Will resistance to ketolides develop in Streptococcus pneumoniae?
    Leclercq R
    J Infect; 2002 Feb; 44 Suppl A():11-6. PubMed ID: 12150490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of community-acquired respiratory tract infections.
    Calbo E; Garau J
    Respiration; 2005; 72(6):561-71. PubMed ID: 16354997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and antibacterial activity of 6-O-arylpropargyl-9-oxime-11,12-carbamate ketolides.
    Beebe X; Yang F; Bui MH; Mitten MJ; Ma Z; Nilius AM; Djuric SW
    Bioorg Med Chem Lett; 2004 May; 14(10):2417-21. PubMed ID: 15109624
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of a computerized template on antibiotic prescribing for acute respiratory infections in children and adolescents.
    Bourgeois FC; Linder J; Johnson SA; Co JP; Fiskio J; Ferris TG
    Clin Pediatr (Phila); 2010 Oct; 49(10):976-83. PubMed ID: 20724348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.